IL1B and atherosclerosis: In a finding particularly relevant to CHIP, as experimental evidence had identified IL-1β-mediated inflammation as a key driver of atherosclerosis in animal models of CHIP, a secondary analysis of the CANTOS trial of patients sought to assess the relationship between CHIP mutations and response to canakinumab39.